ARTICLE | Company News
AstraZeneca, CRI, Ludwig Institute deal
October 15, 2012 7:00 AM UTC
The institutes will conduct clinical trials of cancer immunotherapy combinations, including three mAbs from AstraZeneca's MedImmune LLC biologics unit as well as other immunotherapies that have yet to be chosen. Funding will be provided by the Cancer Research Institute's Cancer Vaccine Acceleration Fund. The institutes are not seeking any ownership rights. Cancer Research Institute is eligible for development milestones, which the institute said will be used for further investment in clinical trials. The partners declined to disclose details. ...